Tegobuvir Completed Phase 2 Trials for Hepatitis C Virus (HCV) Infection Treatment

Indications	Status	Purpose	Phase
DBCOND0052122 (Hepatitis C Virus (HCV) Infection)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00743795	Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Ribavirin (DB00811) Tegobuvir (DB11852)
NCT01072695	Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection	GS-9256 (DB12876) Peginterferon alfa-2a (DB00008) Ribavirin (DB00811) Tegobuvir (DB11852)